Overview
Bioceres fiscal Q1 revenue declines 17% yr/yr, missing analyst expectations
Adjusted EBITDA for fiscal Q1 rises 61%, beating analyst expectations
Company focuses on margin expansion and cost discipline amid revenue decline
Outlook
Company prioritizes strengthening capital structure and financial flexibility
Result Drivers
REVENUE DECLINE - Co attributes 17% revenue decline to strategic shift away from low-margin sales and timing issues in Latam markets
MARGIN EXPANSION - Gross margin increased from 40% to 47% due to a more profitable product mix
WORKING CAPITAL IMPROVEMENT - Co reports improved working capital efficiency despite seasonally high needs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Miss | $77.50 mln | $90.23 mln (4 Analysts) |
Q1 Adjusted EBITDA | Beat | $13.60 mln | $11.02 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the agricultural chemicals peer group is "buy."
Wall Street's median 12-month price target for Bioceres Crop Solutions Corp is $5.00, about 61.4% above its November 11 closing price of $1.93
Press Release: ID:nBw66KzD0a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)